

Health **FAX**

Universal Influenza Immunization Program (UIIP) 2012-2013.

Welcome Participating Pharmacies

Attention: Pharmacists Participating in UIIP 2012-2013

Date: October 22, 2012

The following information is being provided to assist you with the provision of flu vaccine to your clients.

Influenza Immunization Recommendations for the 2012-2013 Season

There have been two NACI Statements published this year with recommendations for the 2012-2013 season:

- The *National Advisory Committee on Immunization (NACI) Statement on Influenza Vaccination for the 2012-2013 Season*
- A *Supplemental Statement of Seasonal Influenza Vaccine for 2012-2013: New Evidence review for children 24-59 months of age.*

These documents can be found on the Public Health Agency of Canada website at the following link:

<http://www.phac-aspc.gc.ca/naci-ccni/index-eng.php>.

Influenza Surveillance

Between September 2011 and January 2012, influenza activity was reported in Africa, the Americas, Asia, Europe and Oceania. Influenza A (H3N2) viruses were predominant in Europe, in many countries in the Americas and northern Africa and Asia. Influenza A (H1N1) pdm09 viruses circulated at very low levels in general with the exception of some countries in Asia and the Americas (including Mexico). Influenza B viruses circulated in many parts of the world and predominated in some countries including China.

While most of the viruses characterized early in 2011-12 season were antigenically related to the virus in the vaccine in the 2011-12 trivalent vaccine, there was evidence of increasing antigenic and genetic drift in the more recently circulating influenza A (H3N2) viruses and the proportion of influenza B viruses that were from the Yamagata lineage had been increasing relative to those from the Victoria lineage. The WHO therefore recommended a change in the formulation of the 2012-2013 influenza season to include an A/Victoria/361/2011 (H3N2)-like virus and a B/Wisconsin/1/2010-like virus of the Yamagata lineage, and to continue the inclusion of the an A/California/7/2009 (H1N1) pdm09-like virus.

Recommended Recipients of Influenza Vaccine for the 2012-2013 Season

Influenza vaccine is encouraged for everyone 6 months of age and older. Immunization with influenza vaccine is **not** recommended for infants less than 6 months of age. The priority groups for influenza vaccination continue to be those at high risk of influenza-related complications, those capable of transmitting influenza to individuals at high risk of complications and those who provide essential community services. (Refer to the table on page 4 for more detailed information about priority groups).

*****New this year - NACI has expanded the high risk groups to include children 6-59 months (rather than just 6-24).**

Pregnancy and Breastfeeding - Influenza vaccination is recommended for all pregnant women regardless of trimester and women who are breastfeeding.

Publicly Funded Influenza Vaccine Products for the 2012/2013 UIIP

There are eight seasonal trivalent influenza vaccines authorized for use in Canada. For the 2012-2013 influenza season, the following vaccines are available publicly funded (free) in Ontario:

Vaccine Products	<p>Vaxigrip® - manufactured by Sanofi Pasteur (10 dose vial)</p> <p>Agriflu® - manufactured by Novartis (single dose prefilled syringe)</p> <p>Fluad® - manufactured by Novartis (for Long Term Care Residents ≥65 years)</p> <p>Fluviral® – manufactured by GlaxoSmithKline (10 dose vial)</p>
-------------------------	--

Vaxigrip®, Agriflu® and Fluad® contain trace amounts of neomycin. All four products are latex free. Vaxigrip® is provided in a multi-dose format (therefore contains trace amount of thimerosal as a preservative) and must be discarded 7 days after puncturing the vial. Fluviral® is also provided in a multi-dose format (therefore contains trace amount of thimerosal as a preservative) and must be discarded in 28 days after puncturing the vial. Agriflu® and Fluad® are provided in single dose pre-filled glass syringes and do not contain thimerosal. For detailed information on each of the vaccine products, refer to their product monographs.

Flumist® (nasal delivery), and Inluvac® (single use, thimerosal free), Fluzone®, and Intanza® (intradermal delivery) are not available publicly funded through the UIIP for the 2012/2013season.

Scheduling and Dosage

Children 6 to 35 months of age should be given a full dose (0.5 mL) of influenza vaccine, not the previously recommended half dose (0.25 mL). This NACI recommendation is based on evidence showing an improvement in antibody response without an increase in adverse effects. This recommendation applies whether the child is being given one dose of the influenza vaccine or a two dose series as per below.

AGE	DOSE (mL)	NUMBER OF DOSES	ROUTE
6 months through 8 years	0.5	1 or 2*	IM
≥ 9 years	0.5	1	IM

***Children less than 9 years of age who are receiving seasonal influenza vaccine for the first time this year are recommended to receive 2 doses, with a minimum interval of 4 weeks between the first and second dose.** The second dose is not needed if the child has received one or more doses of the seasonal influenza vaccine during a previous influenza season.

Individuals with an Egg Allergy

Prior to 2011-2012, NACI statements have advised that those with a known IgE-mediated hypersensitivity to eggs not be routinely immunized with influenza vaccine manufactured in eggs. **However, after review of a number of studies that demonstrate most egg-allergic individuals can safely receive inactivated influenza vaccine and guidelines for vaccination that have been developed by a number of professional groups, NACI concluded that egg-allergic individuals may be vaccinated against influenza. (Refer to this year’s NACI Statement for more detailed information).**

The risk of severe allergic reaction or anaphylaxis in egg-allergic individuals can be determined by assessing the history of reactions to egg. The Canadian Society of Allergy and Clinical Immunology CSACI considers an egg-allergic individual to be at **lower risk for severe allergic reactions** if they have mild gastrointestinal or mild local skin reaction, can tolerate ingestion of small amounts of egg, or have a positive skin/specific IgE test to egg when exposure is unknown. An egg-allergic individual is considered to be at **higher risk for severe allergic reactions** if they have had a previous respiratory or cardiovascular reaction or generalized hives when exposed to egg, or have poorly controlled asthma.

Two vaccine delivery protocols can be used for egg-allergic individuals, depending on their level of risk for an allergic reaction. Egg-allergic individuals at lower risk for severe allergic reaction can be vaccinated for influenza using a single **full dose** of flu vaccine. The **two-step graded dosing** protocol is recommended for individuals who are at higher risk for severe allergic reaction. These two protocols are outlined as follows in the NACI Statement:

Full dose - A single vaccine dose without the use of a graded challenge. Individuals should be observed for 30 minutes following administration for symptom development.

Two-step graded dosing - A two-step graded process, whereby 10% of the age-appropriate dose is administered followed by 30 minutes of observation. If no symptoms develop, or symptoms are self-resolving, administer the remaining 90% with another 30 minute observation period. If sustained or severe reactions arise after the initial dose, the vaccine is withheld and the individual should be re-evaluated for receipt of the influenza vaccine.

Guillain-Barre Syndrome (GBS)

In previous NACI Statements, it was recommended that flu vaccine not be given to individuals who had developed **GBS** within 8 weeks of receiving a previous dose of influenza vaccine. This timeframe has been revised in this year's NACI Statement to **within 6 weeks of receiving a previous dose of influenza vaccine**.

Vaccine Ordering & Availability

Influenza vaccine will be available for pick up, from the Health Unit office nearest to your location once you have met all of the prequalification requirements. The first orders should be directed to persons at high risk as per the table on page 4. All vaccine orders for influenza vaccine must be accompanied by the previous 4 week vaccine refrigerator temperature log. Orders received by Wednesday will be available for pick up on the following Tuesday. The vaccine order form is included on page 5.

For more information, support materials and forms refer to the following websites:

www.simcoemuskokahealth.org – information for health care providers can be found in the *Just for You* section
www.ontario.ca/flu - Ministry of Health and Long-Term Care Universal Influenza Immunization Program Website.

Reporting of Adverse Events

The attached *Adverse Event Following Immunization (AEFI)* form must be filled out and faxed back to the Vaccine Preventable Disease team for follow-up immediately following an unexpected adverse event: **Fax 705-721-1495**.

Reminder: The Health Unit also offers UIIP clinics every Wednesday and Saturday, across the County and District, in November, starting November 3. The HU has moved to an online appointment booking system for our community flu clinics. People can visit the health unit's website, www.simcoemuskokahealth.org, and click on the hot button on the home page that will go directly to the clinic booking system. People will be able to choose the clinic they would like to attend and then select a time for their appointment.

If you have any questions or comments please contact the Vaccine Preventable Disease Program or Health Connection at 705-721-7520 or 1-877-721-7520 extension 8806.

Recommended Recipients of Influenza Vaccine for the 2012-2013 Season

People at high risk of influenza-related complications:

- Adults and children with underlying health conditions
- People of any age who are residents of nursing homes and other chronic care facilities
- People ≥65 years of age
- Healthy children 6 to 59 months of age
- All pregnant women
- Aboriginal peoples

People capable of spreading influenza to those at high risk:

- Health care and other care providers in facilities and community settings who, through their activities, are capable of transmitting influenza to those at high risk of influenza complications.
- Household contacts (adults and children) of individuals at high risk of influenza-related complications (whether or not the individual at high risk has been immunized):
 - household contacts of individuals at high risk, as listed in the section above;
 - household contacts of infants <6 months of age as these infants are at high risk of complications from influenza but cannot receive influenza vaccine; and
 - members of a household expecting a newborn during the influenza season.
- Those providing child care to children ≤59 months of age, whether in or out of the home.
- Those who provide services within closed or relatively closed settings to persons at high risk (e.g. crew on a ship).

Others

- People who provide essential community services
- People in direct contact during culling operations with poultry infected with avian influenza.

*Note: Healthy persons aged 5 to 64 years without contraindication are also encouraged to receive influenza vaccine even if they are not in one of the priority groups.

[Influenza Vaccine Order Form page 5](#)

[Report of Adverse Event Following Immunization Form](#) – pages 6 -9

Pharmacy: _____
 Phone #: _____
 Fax #: _____
 Contact Person: _____

TEL: 705-721-7520 1-877-721-7520

Fax: 705-721-1495 **ATTENTION:** Vaccine Order Desk

Vaccine Order Desk Ext: 8808 General Vaccine/Immunization Inquiries Ext. 8806

Please order in **doses**. Orders placed by **Wednesday** will be available for pick up the following **Tuesday**.

*****All orders must be accompanied by the temperature log for the previous four weeks*****

*****Coolers must be between 2-8 Degrees Celsius for vaccine to be released*****

Antigen	# of Doses
Influenza (10 doses/box)	

Location to be picked up from (please check):

- | | | |
|---|---|--|
| <input type="checkbox"/> Barrie Office | <input type="checkbox"/> Collingwood Office | <input type="checkbox"/> Cookstown Office |
| <input type="checkbox"/> Gravenhurst Office | <input type="checkbox"/> Huntsville Office | <input type="checkbox"/> South Muskoka Memorial Hospital |
| <input type="checkbox"/> Orillia Office | <input type="checkbox"/> Midland Office | |

BIOS Order # (for office use only): _____

Barrie:
 15 Sperling Drive
 Barrie, ON
 L4M 6K9
 705-721-7520
 FAX: 705-721-1495

Collingwood:
 280 Pretty River Pkwy.
 Collingwood, ON
 L9Y 4J5
 705-445-0804
 FAX: 705-445-6498

Cookstown:
 2-25 King Street S.
 Cookstown, ON
 LOL 1L0
 705-458-1103
 FAX: 705-458-0105

Gravenhurst:
 2-5 Pineridge Gate
 Gravenhurst, ON
 P1P 1Z3
 705-684-9090
 FAX: 705-684-9887

Huntsville:
 34 Chaffey St.
 Huntsville, ON
 P1H 1K1
 705-789-8813
 FAX: 705-789-7245

Midland:
 B-865 Hugel Ave.
 Midland, ON
 L4R 1X8
 705-526-9324
 FAX: 705-526-1513

Orillia:
 120-169 Front St. S.
 Orillia, ON
 L3V 4S8
 705-325-9565
 FAX: 705-325-2091



REPORT OF ADVERSE EVENTS FOLLOWING IMMUNIZATION (AEFI)

INSTRUCTIONS: For more complete instructions and definitions, refer to the user guide at:

<http://www.phac-aspc.gc.ca/im/aefi-form-eng.php>

Report events which have a temporal association with a vaccine and which cannot be clearly attributed to other causes. A causal relationship does not need to be proven, and submitting a report does not imply causality.

Of particular interest are those AEFIs which meet one or more of the following criteria:

- a. Are of serious nature
- b. Require urgent medical attention
- c. Are unusual or unexpected events

Refer to the user guide, Background Information and for additional clarification.

NOTE:

- The numbers below correspond to the numbered sections of the form.
 - All dates should be captured in the following format: YYYY/MM/DD.
 - When reporting an AEFI, check one of the boxes on the top right hand corner of the first page of the AEFI form to indicate whether it is an **INITIAL** or **FOLLOW UP** report. For all follow up reports, please specify the **Unique Episode number**.
- 1a. The “**Unique episode number**” is assigned by the Province/Territory. Leave it blank unless authorized to assign it.
 - 1b. The “**Region number**” is a number that corresponds to a given health unit. Leave it blank if it doesn’t apply to your locale.
 2. The “**IMPACT LIN**” is assigned by IMPACT nurse monitors (LIN: Local Inventory Number).
 3. The information provided in this section is confidential and should not be sent to the Public Health Agency of Canada.
 - 4a. Indicate the Province/Territory where the vaccine was administered, abbreviations may be used.
 - 4c. Provide all information as requested in the table. For the “**Dose #**”, provide the number in series (1, 2, 3, 4, or 5) if known. For the Influenza vaccine, unless a patient receives two doses in one season, the “**Dose #**” should be recorded as “1”.
 - 7a. Indicate the highest impact of the AEFI on the patient’s daily activities as assessed by the patient or the parent/caregiver.
 - 7c. Provide details of any investigations or treatments in section 10. If the patient was already in hospital when immunized and the immunization resulted in a longer hospital stay, indicate “**Resulted in prolongation of existing hospitalization**” and provide the number of days by which the patient’s hospital stay was prolonged. For all hospitalizations, indicate the date of admission and discharge.
 8. MOH/MHO: Medical Officer of Health, MD: Medical Doctor, RN: Registered Nurse.
 9. Choose, from section 9 (AEFI details), the description that best fits the AEFI being reported. Make sure to record the time of onset and duration of signs/symptoms using the most appropriate time unit:
 - If the interval is <1 hour, indicate in minutes;
 - If it is ≥ 1 hour but <1 day; indicate in hours;
 - If it is ≥1 day; indicate in days.
 Report the time in one time unit only. Provide additional details of any investigation, therapy, and other information as appropriate in section 10.
 11. This section is to be completed by the MOH/MHO, MD, RN or their designate who are assigned to provide public health recommendations according to the P/T best practices.
 12. Information in this section is not collected by all P/Ts.

Return completed form to your local public health unit address at:

Alberta (AB)	Northwest Territories (NT)	Quebec (QC)
British Columbia (BC)	Nova Scotia (NS)	Saskatchewan (SK)
Manitoba (MB)	Nunavut (NU)	Yukon (YT)
New Brunswick (NB)	Ontario (ON)	Public Health Agency of Canada (PHAC)
Newfoundland and Labrador (NL)	Prince Edward Island (PE)	



REPORT OF ADVERSE EVENTS FOLLOWING IMMUNIZATION (AEFI)

1a. Unique episode #: _____ **1b. Region #:** _____ **2. IMPACT LIN:** _____

3. Patient Identification

First name: _____ Last name: _____ Health number: _____
Address of usual residence: _____
Province/Territory: _____ Postal code: _____ Phone: () - (ext #:)
Information Source: First name: _____ Last name: _____ Relation to patient: _____
Contact info, if different: _____

4. Information at Time of Immunization and AEFI Onset

4a. At time of immunization
Province/Territory of immunization: _____
Date vaccine administered: YYYY / MM / DD (hr: am/pm)
Date of birth: YYYY / MM / DD Age: _____
Sex: Male Female Other

4b. Medical history (up to the time of AEFI onset)
(Check all that apply and provide details in section 10)
 Concomitant medication(s)
 Known medical conditions/allergies
 Acute illness/injury

4c. Immunizing agent	Trade name	Manufacturer	Lot number	Dose #	Dosage/unit	Route	Site
					/		
					/		
					/		
					/		
					/		

5. Immunization Errors
Did this AEFI follow an incorrect immunization? No Unknown Yes
(If Yes, choose all that apply and provide details in section 10)
 Given outside the recommended age limits Product expired
 Wrong vaccine given Incorrect route
 Dose exceeded that recommended for age Other, specify: _____

6. Previous AEFI
Did an AEFI follow a previous dose of any of the above immunizing agents (Table 4c)?
(Choose one of the following)
 No Yes (Provide details in section 10)
 Unknown Not applicable (no prior doses)

7. Impact of AEFI, Outcome, and Level of Care Obtained

7a. Highest impact of AEFI: (Choose one of the following)
 Did not interfere with daily activities
 Interfered with but did not prevent daily activities
 Prevented daily activities

7b. Outcome at time of report:
 Death * Date: YYYY / MM / DD Permanent disability/incapacity *
 Not yet recovered * Fully recovered Unknown
(Provide details in section 10 for items with *)

7c. Highest level of care obtained: (Choose one of the following)
 Unknown None Telephone advice from a health professional Non-urgent visit Emergency visit
 Required hospitalization (___days) **OR** Resulted in prolongation of existing hospitalization (by ___days)
Date of hospital admission YYYY / MM / DD Date of hospital discharge YYYY / MM / DD

7d. Treatment received: No Unknown Yes (Provide details of all treatments including self treatment, in section 10)

8. Reporter Information

Setting : Physician office Public health Hospital Other, specify: _____
Name: _____ Phone: () - (ext #:) Fax: () -
Address: _____
City: _____ Prov/Terr: _____ Postal code: _____ Date reported: YYYY / MM / DD
Signature: _____ MD RN IMPACT Other, specify: _____

Unique episode #:

Region #:

IMPACT LIN:

9. AEFI Details: Complete all sections as appropriate; for each, check all signs/symptoms that apply. Item(s) with asterisk (*) should be diagnosed by a physician. If not, provide sufficient information to support the selected item(s). Use Section 10 for additional information including, clinical details and test results.

9a. Local reaction at or near injection site Interval: ... Duration: ...

Infected abscess Sterile abscess Cellulitis Nodule Reaction crosses joint Lymphadenitis Other, specify:

For any injection site reaction indicated above, check all that apply below and provide details in section 10:

Swelling Pain Tenderness Erythema Warmth Induration Rash Largest diameter of injection site reaction: ... cm Site(s) of reaction ...

9b. Allergic and Allergic-like events Interval: ... Duration: ...

Chose one of the following: Anaphylaxis Oculo-Respiratory Syndrome (ORS) Other allergic events

For a chosen event, check all that apply below and provide details in section 10:

Skin /mucosal Urticaria Erythema Pruritis Prickle sensation Rash ... ANGIOEDEMA: Tongue Throat Uvula Larynx Lip ... EYE(S): Red bilateral Red unilateral Itchy

9c. Neurologic events Interval: ... Duration: ...

* Meningitis * Encephalopathy/Encephalitis * Guillain-Barre Syndrome (GBS) * Bell's Palsy * Other Paralysis Seizure * Other neurologic diagnosis, specify:

For any neurologic event indicated above, check all that apply below and provide details in section 10:

Depressed/alterd level of consciousness, lethargy or personality change lasting >=24hrs Focal or multifocal neurologic sign(s) Fever (>=38.0 C) CSF abnormality EEG abnormality EMG abnormality Neuroimaging abnormality Brain/spinal cord histopathologic abnormality

Seizure details: Witnessed by healthcare professional Yes No Unknown Sudden loss of consciousness Yes No Unknown Focal OR Generalized (Specify: Tonic Clonic Tonic-Clonic Atonic) Previous history of seizures (Specify: Febrile Afebrile Unknown type)

9d. Other defined events of interest Interval: ... Duration: ...

For all selected defined events of interest below, provide details in section 10:

Hypotonic-Hyporesponsive Episode (age <2 years) Limpness Pallor/cyanosis ... *Thrombocytopenia Platelet count <150x10^9/L Petechial rash ... Persistent crying ... Anaesthesia/Paraesthesia ... Intussusception ... Arthritis Joint redness Joint warm to touch ... Fever >=38.0 C ... Rash (Non-allergic) Generalized Localized ... Other severe or unusual event(s) not listed above

